secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-211973
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jade Biosciences Q1 net loss $40.4M, cash $311.3M; pipeline and CMO appointment
-------------------------------------------------------------------------------

- Net loss $40.4M for Q1 2026 vs $38.2M in Q1 2025, driven by higher R&D and G&A costs.
- Cash, equivalents, and investments $311.3M at March 31, 2026; funding expected into first half 2028.
- JADE101 Phase 1 interim biomarker data to be presented at ERA Congress; Phase 2 in IgAN expected Q2 2026.
- JADE201 Phase 1 trial in rheumatoid arthritis expected to start Q2 2026; interim data in 2027.
- Appointed Edward R. Conner, M.D., as CMO; promoted Andrew King to President, R&D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526211973/0001193125-26-211973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526211973/d108669d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-211973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer